PRECISION BIOSCIENCES INC (DTIL) - Dilution Analysis

10-Q filing | 24.6M shares outstanding

10-K filing | 24.7M shares outstanding

8-K filing: Precision BioSciences, Inc. announced an offering of 10,815,000 shares of common stock and accompanying one-half warrants to purchase up to 5,407,500 shares of common stock at a combined price of $6.14, and pre-funded warrants to purchase up to 1,400,000 shares of common stock and accompanying one-half warrants to purchase up to 700,000 shares of common stock at a combined price of $6.139995, with the offering expected to close on November 12, 2025.

10-Q filing | 13.3M shares outstanding

10-Q filing | 11.0M shares outstanding

10-Q filing | 11.1M shares outstanding

10-K filing | 10.5M shares outstanding

8-K filing: Precision BioSciences issued 220,712 shares of its common stock to TG Subsidiary on January 6, 2025, for a deferred cash payment of $2.5 million. ($2.5M proceeds)

10-Q filing | 7.3M shares outstanding

10-Q filing | 7.0M shares outstanding

10-Q filing | 6.9M shares outstanding

8-K filing: Precision BioSciences, Inc. has entered into a definitive subscription agreement to issue and sell 25,000 shares of its common stock in a non-brokered private placement to certain members from its management at $12.00 per share, for aggregate gross proceeds of approximately $300,000. ($0.3M proceeds)

10-K filing | 6.9M shares outstanding

8-K filing: Precision BioSciences, Inc. entered into an underwriting agreement for an offering of 2,500,000 shares of common stock and accompanying warrants, with an option for the underwriter to purchase up to 375,000 additional shares and warrants. ($40.0M proceeds)

8-K filing: Stock split 1-for-30 | Outstanding: 115,174,752 → 3,839,158

8-K filing: Precision BioSciences, Inc. will issue shares of its common stock to TG Subsidiary in exchange for cash payments related to a License Agreement for the development, manufacture, and commercialization of azer-cel, with 2,920,816 shares to be issued for $2.25 million as part of the upfront payment. ($2.25M proceeds)

10-Q filing | 115.2M shares outstanding

8-K filing: Precision BioSciences, Inc. entered into an Asset Purchase Agreement with Imugene Limited, selling its manufacturing infrastructure for $8 million in cash and $13 million in convertible notes, and a License Agreement granting Imugene rights to develop and commercialize oncological applications of azer-cel.

10-Q filing | 114.1M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-Q filing | 111.3M shares outstanding

10-K filing | 111.3M shares outstanding

10-Q filing | 110.8M shares outstanding

10-Q filing | 110.8M shares outstanding

8-K filing: Precision BioSciences, Inc. entered into an underwriting agreement with Jefferies LLC for the offering, issuance, and sale of 35,971,224 shares of common stock at $1.39 per share, with the closing expected on June 24, 2022. ($50.0M proceeds)

8-K filing: Precision BioSciences, Inc. sold 12,407,440 shares of its common stock to Novartis for $25.0 million, at a price of approximately $2.01 per share, in a private placement transaction. ($25.0M proceeds)

10-Q filing | 62.2M shares outstanding

10-K filing | 61.0M shares outstanding

10-Q filing | 60.8M shares outstanding

10-Q filing | 59.8M shares outstanding

10-Q filing | 57.5M shares outstanding

10-K filing | 57.0M shares outstanding

8-K filing: Precision BioSciences closed a stock purchase agreement with Lilly, issuing 3,762,190 shares of common stock for $35 million. ($35.0M proceeds)

8-K filing: Precision BioSciences, Inc. entered into a development and license agreement with Eli Lilly and Company, including an equity investment where Lilly purchased 3,762,190 shares of Precision BioSciences' common stock at $9.30 per share for $35 million. ($35.0M proceeds)

10-Q filing | 52.5M shares outstanding

10-Q filing | 52.3M shares outstanding

S-3 filing: The company intends to use the net proceeds of this offering to advance the clinical development of its lead allogeneic CAR T cancer immunotherapy programs targeting CD19, CD20 and BCMA, advance the development of our CAR T cancer immunotherapy platform, further progress our in vivo gene correction portfolio, fund new and ongoing research and development activities, and fund the portion of expenses we are responsible for with respect to the development of our food platform, and for working capital and other general corporate purposes.

10-Q filing | 51.9M shares outstanding

10-K filing | 51.4M shares outstanding